NCT06161558 2025-07-16
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
Clinical Trials
48 trialsNCT02743546 2025-02-03
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT06372574 2024-09-03
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
Genentech, Inc.
Phase 1 Withdrawn
NCT05678283 2024-04-17
A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT05431582 2023-06-15
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05060276 2023-01-26
Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors
Sorrento Therapeutics, Inc.
Phase 1 Withdrawn
NCT03906643 2022-12-20
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies
Duke University
Phase 1 Withdrawn
NCT05253105 2022-05-31
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Withdrawn
NCT03606655 2020-01-13
Exploring the Impact of Two-week Kava on the Metabolism of Nicotine and NNK
University of Florida
Phase 1 Withdrawn
NCT02582827 2019-08-28
QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas
NantBioScience, Inc.
Phase 1 Withdrawn
NCT02611908 2019-01-25
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
University of California, San Diego
Phase 1 Withdrawn
NCT02939846 2018-09-14
Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours
GlaxoSmithKline
Phase 1 Withdrawn
NCT00352950 2018-09-06
Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer
Amgen
Phase 1 Withdrawn
NCT02914327 2018-07-30
Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
Esanex Inc.
Phase 1 Withdrawn
NCT03077477 2018-06-14
Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers
Aminex Therapeutics, Inc.
Phase 1 Withdrawn
NCT03422874 2018-02-06
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
Dartmouth-Hitchcock Medical Center
Phase 1 Withdrawn
NCT02106871 2017-10-27
PCC
The University of Texas Medical Branch, Galveston
Phase 1 Withdrawn
NCT02745756 2017-08-30
A Combined Cell Therapy Approach to the Treatment of Neuroblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT02674555 2017-07-28
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors
Astellas Pharma Inc
Phase 1 Withdrawn
NCT01130623 2017-07-02
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT01236586 2017-07-02
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT02723838 2017-03-07
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
Oncolytics Biotech
Phase 1 Withdrawn
NCT01974258 2016-11-02
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Hoffmann-La Roche
Phase 1 Withdrawn
NCT02380313 2016-10-06
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
GlaxoSmithKline
Phase 1 Withdrawn
NCT02556346 2016-03-02
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Molecular Templates, Inc.
Phase 1 Withdrawn
NCT02292732 2016-01-26
A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Withdrawn
NCT00704392 2015-08-20
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
Exelixis
Phase 1 Withdrawn
NCT00666081 2015-04-17
Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies
GlaxoSmithKline
Phase 1 Withdrawn
NCT00247403 2015-04-10
Safety Study of 2DG With Stereotactic Radiosurgery
University of Iowa
Phase 1 Withdrawn
NCT02312804 2015-02-16
Ph Ib/BGJ398/Cervix and Other Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Withdrawn
NCT00024674 2014-11-14
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days
INSYS Therapeutics Inc
Phase 1 Withdrawn
NCT00024687 2014-11-14
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
INSYS Therapeutics Inc
Phase 1 Withdrawn
NCT01348997 2014-10-07
E-health Intervention for Cancer Survivors 2.0
Northwestern University
Phase 1 Withdrawn
NCT01969682 2014-05-26
A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199
AbbVie
Phase 1 Withdrawn
NCT00957320 2013-12-03
Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)
Emory University
Phase 1 Withdrawn
NCT01567384 2013-11-20
A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies
Emory University
Phase 1 Withdrawn
NCT01197209 2013-08-23
Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer
Momotaro-Gene Inc.
Phase 1 Withdrawn
NCT01437280 2013-08-14
GOAT
Baylor College of Medicine
Phase 1 Withdrawn
NCT00942838 2013-07-24
WAR
University of Utah
Phase 1 Withdrawn
NCT00006106 2013-07-10
ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT01031212 2013-05-13
ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors
University of California, San Francisco
Phase 1 Withdrawn
NCT00935142 2013-01-25
[18F]VM4-037
Maastricht Radiation Oncology
Phase 1 Withdrawn
NCT00137358 2013-01-24
Radiation With Chemotherapy and a Study Drug to the Para-Aortic Nodes in Cervical Cancer
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT00520325 2012-09-05
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia
Enzon Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT00442741 2012-04-25
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)
Novartis
Phase 1 Withdrawn
NCT01146171 2012-02-07
Japanese Phase 1 Study of BMS-844203 (CT322)
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT01194193 2011-05-16
Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours
AstraZeneca
Phase 1 Withdrawn
NCT01000896 2010-02-04
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
AstraZeneca
Phase 1 Withdrawn